Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsSanford Health Plan Synagis Prior Auth Coverage | …
    Ask Trek AI about this page
    Currentsanford health planPolicy N/A

    Synagis (palivizumab) prior authorization form coverage criteria

    Customize your policy alerts

    Sign up for all sanford health plan policy alerts

    Know when sanford health plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Template and requirements for prior authorization of Synagis (palivizumab) for pediatric members of Sanford Health Plan; directs providers on information and documentation needed to request coverage (including clinical details for specific high-risk groups).

    Policy Summary
    Payersanford health plan
    PolicySynagis (palivizumab) prior authorization form coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed, legible prior authorization form (fax or online) with required supporting documentation to request up to 5 doses during the Nov 15–Apr 15 season.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    up to 5maximum doses covered if approved
    Nov 15-Apr 15coverage season
    fax (701) 234-4568fax to submit form
    (800) 752-5863Pharmacy contact

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage criteria for Synagis (palivizumab)

    General eligibility and submission

    Coverage may be approved when the provider submits a completed, legible prior authorization form with required documentation showing the infant meets one of the high‑risk group criteria and therapy is requested within the RSV season; approvals cover up to 5 doses during the season.

    General submission requirements: Completed, legible prior authorization form submitted via fax to (701) 234-4568 or online through the provider portal; indicate whether request is New or Continuation and, if continuation, provide original therapy start date; include medication details (strength, quantity, days' supply, HCPCS if applicable), prescriber information, signature, and medical rationale.

    Prior authorizations cannot be completed by phone; attach required clinical documentation to support the selected high-risk group.

    Chronic Lung Disease (CLD) of prematurity

    Preterm infants with chronic lung disease of prematurity

    CLD criteria: Infant required >21% oxygen for at least the first 28 days after birth AND in the past 6 months required chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen (if applicable).>21% oxygen for 28 days

    Provider must attach clinical documentation verifying oxygen requirement and any chronic therapies or pharmacy records.

    Congenital Heart Disease (CHD)

    Infants with hemodynamically significant congenital heart disease (CHD)

    CHD criteria: Provider lists medications used to control congestive heart failure or pulmonary hypertension; indicates whether infant will require cardiac surgical procedures, has moderate-to-severe pulmonary hypertension, or has undergone/will undergo cardiac transplantation during the RSV season.

    Attach a letter of medical necessity from a pediatric cardiologist and supporting documentation (medication lists, surgical plans).

    Anatomic pulmonary / Neuromuscular disease

    Children with anatomic pulmonary abnormalities or neuromuscular disease

    Anatomic/neuromuscular criteria: Provide clinical documentation that the infant has a neuromuscular disease or congenital anatomic abnormality that impairs the ability to clear upper airway secretions.

    Attach relevant clinical records or specialist notes describing the impairment in airway clearance.

    Immunocompromised infants

    Immunocompromised children

    Immunocompromised criteria: Provide clinical documentation supporting that the infant is profoundly immunocompromised.

    Attach laboratory data, treatment records, or specialist documentation demonstrating the immunocompromised state.

    Cystic Fibrosis (CF)

    Children with Cystic Fibrosis

    CF criteria: In the past 6 months the infant required chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen OR was hospitalized in the first year of life for a pulmonary exacerbation OR has persistent abnormalities on chest radiography/CT when stable OR has weight less than the 10th percentile.weight <10th percentile

    Attach clinical documentation, pharmacy records, hospitalization records, imaging reports, or growth records as applicable.

    The prior authorization form does not list any explicit clinical exclusions. The form includes a checkbox to request retroactive coverage for a previous claim or date of service and provides a field to record the applicable date of service, allowing providers to indicate that coverage is being sought after-the-fact.

    The policy states that the Plan's decision will be based on the member's individual plan policy and the clinical documentation submitted. The form does not enumerate discrete "not medically necessary" conditions; determinations about medical necessity or exclusions will be made by Sanford Health Plan according to each member's plan rules and the supporting clinical information provided with the request.

    Initial therapy requirements

    Initial therapy

    Initial therapy requests require full completion of the prior authorization form and submission of supporting documentation for the indicated high‑risk group.

    Initial therapy submission: Complete medication fields (strength, quantity, day’s supply, HCPCS if applicable), mark request as 'New', provide medical rationale and expected length of therapy, and attach necessary documentation for the indicated risk group.

    If approved, coverage applies to up to 5 doses administered between November 15 and April 15; retroactive coverage must be indicated on the form with date of service.

    Continuation therapy requirements

    Continuation therapy

    Continuation requests require documentation that therapy was previously started and justification for ongoing dosing.

    Continuation therapy documentation: For continuation requests, indicate 'Continuation' on the form and provide the original therapy start date, clinical rationale for ongoing treatment, and supporting records (e.g., prior authorization approval, administration records).

    Field present on form for continuation indication; attach supporting records to justify continued dosing within the season.

    Billing and diagnosis codes

    Provider-supplied billing codeHCPCS
    HCPC (if applicable)Field for provider to supply HCPCS code for medication/billing
    Diagnosis codesICD-10
    PRIMARY DIAGNOSIS (ICD-10 CODE)Primary diagnosis ICD-10 code field
    SECONDARY DIAGNOSIS (ICD-10 CODE)Secondary diagnosis ICD-10 code field
    inv-11: Oxygen requirement for CLD
    Oxygen threshold> 21% oxygen for at least the first 28 days after birth
    Documentation requiredAttach clinical documentation supporting >21% oxygen use for at least the first 28 days after birth
    Additional 6‑month criteriaIn past 6 months, record whether infant required chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen; attach supporting records if yes
    inv-12: Low weight criterion for CF
    Weight thresholdWeight less than the 10th percentile
    Associated CF criteriaIn past 6 months required chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen — provide documentation if yes

    Submission, documentation, and approval actions for providers

    Prior Authorization

    Submit completed PA form; approval covers up to 5 seasonal doses

    Submit a fully completed and legible prior authorization form by fax to (701) 234-4568 or online through the provider portal; approvals, if granted, will cover up to 5 doses to be given between November 15 and April 15 of the season.

    • Fax completed form to (701) 234-4568 or submit online at sanfordhealthplan.com/providerlogin.
    • Approvals cover up to 5 doses given between November 15 and April 15.
    Step Therapy

    Provide start date and rationale for continuation requests

    For continuation requests, indicate “Continuation of therapy” on the form and provide the original therapy start date plus clinical rationale and supporting records to justify ongoing dosing.

    • Check the “Continuation of therapy” box and enter the start date on the form.
    • Attach supporting records and clinical rationale demonstrating need for continued therapy.

    Key patient data fields required on the form

    inv-18: Gestational Age
    Required fieldRecord member's gestational age in weeks and days (e.g., ___ Weeks ___ Days)
    Placement on formCollected in Member Information section of the prior authorization form
    PurposeUsed to determine eligibility for high‑risk groups such as CLD of prematurity
    inv-19: Member's Current Weight
    Required fieldRecord member's current weight in kilograms and the date recorded (e.g., ___ kg Date Recorded)
    Dosing relevanceWeight is used to guide palivizumab dosing for the season
    Documentation

    Quantity limits and dosing

    inv-23: Synagis (palivizumab)
    Maximum doses per approved requestUp to 5 doses per season (if approved)
    Season windowDoses to be given between November 15 and April 15
    Approval sourceCoverage of up to 5 doses stated in the Plan's approval instructions on the prior authorization form

    Site of care and administration notes

    Note

    No site-of-care restriction specified

    The form does not impose a site-of-care restriction; no specific site limitation is specified on the prior authorization form.

    Step therapy and prior trial requirements

    StepForm field / requirementDetails
    New vs Continuation
    Provider must indicate whether the requested therapy is 'New' or 'Continuation of therapy' (checkboxes on form). If continuation is selected, the form requires the original therapy start date.
    Form collects this as a single-step selection only; no multi-step drug trial or step-failure series is specified on the form—providers simply mark New or Continuation and, for continuation, supply the start date.

    Background on Synagis (palivizumab)

    Synagis (palivizumab) is an RSV prophylactic monoclonal antibody indicated to help prevent severe respiratory syncytial virus disease in certain high-risk pediatric populations. The form is structured to collect clinical information and documentation to assess eligibility for infants and children with conditions including chronic lung disease of prematurity (CLD), hemodynamically significant congenital heart disease (CHD), certain anatomic pulmonary or neuromuscular disorders, profound immunocompromise, and cystic fibrosis with complications so that the Plan can determine coverage for up to the authorized doses during the RSV season.

    Policy Summary
    Payersanford health plan
    PolicySynagis (palivizumab) prior authorization form coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed, legible prior authorization form (fax or online) with required supporting documentation to request up to 5 doses during the Nov 15–Apr 15 season.
    SourceLink
    On This Page
    Coverage criteria for Synagis (palivizumab)Initial therapy requirementsContinuation therapy requirementsBilling and diagnosis codesSubmission, documentation, and approval actions for providersKey patient data fields required on the formQuantity limits and dosingSite of care and administration notesStep therapy and prior trial requirementsBackground on Synagis (palivizumab)
    Other supporting CF findingsHospitalization in first year of life for pulmonary exacerbation or persistent chest radiography/CT abnormalities — attach documentation
    Documentation Required

    Attach clinical documentation, labs, pharmacy records, and letters of medical necessity

    Attach all relevant clinical documentation to support the diagnosis and qualifying criteria for the infant’s risk group, including lab results, pharmacy records, and letters of medical necessity as applicable.

    • Clinical records showing oxygen use, chronic therapies, or hospitalizations as required by the indicated risk group.
    • Pharmacy records or medication lists for chronic corticosteroid/diuretic therapy or heart-failure medications.
    • Letter of medical necessity from pediatric cardiologist when CHD criteria are claimed.
    Denial Risk

    Do not submit PA requests by phone; ensure form is complete and legible

    Prior authorizations cannot be completed by phone; all fields must be completed and legible—incomplete or illegible submissions may delay or prevent approval.

    • All fields must be completed and legible for review.
    • Prior authorizations cannot be completed over the phone.
    Enter weight and date in the Member Information section of the prior authorization form